Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples